Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40384 __________________________________________________________ TOURMALINE BIO, ...

Exhibit 99.1 Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing – — Additional data from the ongoing Phase 2 TRANQUILITY trial to be presented at the European Society of Cardiology Congress in August 2025 – NEW YORK – August 13, 2025 – Tourmaline Bio, I ...

财务数据关键指标变化：收入和利润 - 2025年第一季度净亏损为2300万美元，2024年同期为1330万美元[96] - 2025年第一季度净亏损为2297.0万美元，同比增长72.6%[124] 财务数据关键指标变化：成本和费用 - 2025年第一季度研发费用为2025.8万美元，同比增长78.1%[124][125] - 2025年第一季度总运营费用为2623.1万美元，同比增长49.7%[124] - 2025年第一季度一般及行政费用为597.3万美元，同比下降2.7%[124][125] - 研发费用增加主要归因于TRANQUILITY和spiriTED试验相关的临床费用增加380万美元[125][127] 财务数据关键指标变化：其他财务数据 - 2025年第一季度其他收入净额为326.1万美元，同比下降22.5%[124][126] - 截至2025年3月31日，公司现金、现金等价物及投资总额为2.753亿美元[95] - 截至2025年3月31日，公司现金、现金等价物及投资总额为2.753亿美元[130] - 截至2025年3月31日，公司累计赤字为1.582亿美元[96] - 公司累计赤字截至2025年3月31日为1.582亿美元[129] - 2025年第一季度经营活动所用现金净额为2170万美元，较2024年同期的1490万美元增加680万美元[139][140] - 2025年第一季度投资活动提供现金净额为2590万美元，而2024年同期为使用现金净额1.889亿美元，主要由于投资到期[139][141] - 2025年第一季度融资活动提供现金净额为56.2万美元，远低于2024年同期的1.614亿美元，主要因2024年1月发行股票所致[139][142] - 2025年第一季度现金及等价物净增加480万美元，而2024年同期为净减少4240万美元[139] 业务线表现：研发管线进展 - 公司主要候选产品pacibekitug针对心血管炎症的2期TRANQUILITY试验预计在2025年第二季度报告顶线数据[90][91] - 公司针对甲状腺眼病的2b期spiriTED试验预计在2025年下半年报告顶线数据[93] 管理层讨论和指引：资金与运营 - 基于当前运营计划，公司预计现有资金可支持运营至2027年下半年[130] - 公司已建立ATM发行计划，可发行至多1.0亿美元的普通股[131][132] 其他重要内容：市场与竞争格局 - 2024年全球抗IL-6或抗IL-6R抗体药物销售额总计超过35亿美元[87] 其他重要内容：许可协议与潜在付款义务 - 根据与辉瑞的许可协议，公司可能需支付高达1.28亿美元的开发和监管里程碑付款，以及高达5.25亿美元的销售里程碑付款[103] - 根据与辉瑞的许可协议，公司需支付低于15%的边际特许权使用费[103] - 根据与龙沙的许可协议，公司需支付低个位数的净销售额特许权使用费[107] - 若产品获批，公司可能需向辉瑞支付最高1.28亿美元的研发监管里程碑付款及最高5.25亿美元的首次销售里程碑付款[138] - 公司商业化后需向辉瑞和龙沙支付基于产品销售额的特许权使用费[138] 其他重要内容：融资活动 - 在反向合并前的融资交易中，公司通过私募配售筹集了7500万美元[100] 其他重要内容：公司身份与报告状态 - 公司作为新兴成长公司，若年收入超过12.35亿美元或非关联方持有权益证券市值达7亿美元等条件将终止该身份[149] - 公司目前是“较小报告公司”，其非关联方持有股票市值低于7亿美元且最近财年收入低于1亿美元[150]

"We continue to see growing evidence and enthusiasm for the potential of addressing IL-6-driven cardiovascular inflammation through our discussions with cardiovascular disease experts, attendance at major medical conferences, and review of constantly emerging scientific literature," said Sandeep Kulkarni, MD, Co- Founder and Chief Executive Officer of Tourmaline. "We look forward to the expected presentation of topline data from our Phase 2 TRANQUILITY trial of pacibekitug later in the second quarter. This ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K _____________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40384 ________________________________________________ ...

Exhibit 99.1 Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 – – Cardiovascular Scientific Advisory Board strengthened with recent appointments of Drs. Deepak L. Bhatt, Dipender Gill, Paul M. Ridker, and Tabassome Simon – – Cash, cash ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40384 __________________________________________________________ TOURMALINE ...

Exhibit 99.1 Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights – On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – NEW YORK, November 7, 2024 – Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced its financial results for the third quarter o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________ (Mark One) TOURMALINE BIO, INC. (Exact name of Registrant as specified in its Charter) ___________________________________________________________ Delaware 83-2377352 (State or other jurisdiction of incorporation or organization) 27 West 24th Street, Suite 702 New York, NY 10010 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40384 __________________________________________________________ TOURMALINE BIO ...